Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Drugs Dermatol ; 22(11): e24-e28, 2023 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-37943271

RESUMEN

INTRODUCTION: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare and dangerous dermatologic emergency. It can have different presentations, especially in patients with multiple drug causes, and definitive management of SJS/TEN in these presentations remains unclear. Systemic corticosteroids, TNF inhibitors, and cyclosporine A are promising therapies. CASE REPORT: In this case report, we present a 55-year-old man who developed SJS/TEN while on pembrolizumab and lamotrigine. The patient was treated with corticosteroids and a single dose of etanercept. After a one-week follow-up, the patient’s SJS/TEN had no new activity. DISCUSSION: This literature review highlights how SJS/TEN may present differently in patients on immune checkpoint inhibitors. Treatments in these cases may vary from those with classic SJS/TEN.  Specifically, etanercept given days late into the disease course is effective in speeding re-epithelialization and tapering of already given corticosteroids in classic SJS/TEN. J Drugs Dermatol. 2023;22(11):e24-e28     doi:10.36849/JDD.6999e.


Asunto(s)
Síndrome de Stevens-Johnson , Masculino , Humanos , Persona de Mediana Edad , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/tratamiento farmacológico , Síndrome de Stevens-Johnson/etiología , Etanercept/uso terapéutico , Ciclosporina , Progresión de la Enfermedad , Corticoesteroides
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...